Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright lowered their price target on Trevena from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 16th.

Trevena Price Performance

TRVN opened at $0.22 on Tuesday. The stock has a 50-day moving average price of $0.39 and a 200-day moving average price of $0.52. The company has a debt-to-equity ratio of 8.35, a current ratio of 3.60 and a quick ratio of 3.60. The firm has a market cap of $4.12 million, a PE ratio of -0.08 and a beta of 1.07. Trevena has a 1 year low of $0.19 and a 1 year high of $1.12.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.01. The company had revenue of $0.02 million during the quarter. Sell-side analysts predict that Trevena will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new position in Trevena, Inc. (NASDAQ:TRVN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena as of its most recent filing with the SEC. 13.56% of the stock is owned by hedge funds and other institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.